Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ana Maria Gonzalez-Angulo

Showing results (71-80 of 75) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 75 results.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
Nature Communications|September 11, 2013
Tumour angiogenesis regulation by the miR-200 familyChad V Pecot, Rajesha Rupaimoole, Da Yang, et al.
Pageof 8

Showing results (71-80 of 75) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 75 results.
Breast Cancer Research : BCR|July 7, 2019
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutationYan Xing, Nancy U Lin, Matthew A Maurer, et al.
Cancer Research|September 14, 2021
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast CancerKurt W Evans, Erkan Yuca, Stephen S Scott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 9, 2014
Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancerRinath Jeselsohn, Roman Yelensky, Gilles Buchwalter, et al.
Cancer Cell|July 4, 2009
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancerKrishna M Vasudevan, David A Barbie, Michael A Davies, et al.
Nature Communications|September 11, 2013
Tumour angiogenesis regulation by the miR-200 familyChad V Pecot, Rajesha Rupaimoole, Da Yang, et al.
Pageof 8